Chirivella I et al. – Dose–response effect is critical in administration of anthracycline-based non-taxane therapy in adjuvant treatment of early breast cancer; for maximal benefit, delayed/reduced chemotherapy should be avoided Methods
Retrospective study of dose–response effect of adjuvant anthracycline-based non-taxane chemotherapy in 793 early breast cancer pts
Results
Review of chemotherapy delivery through number of delayed cycles, number of delayed days and relative dose intensity (RDI) administered
On Kaplan–Meier analysis, number of delayed cycles and delayed days and RDI affected disease-free survival (DFS) and overall survival
On Cox regression analysis with number of affected nodes and hormonal receptor status controlled, all study variables maintained significance for DFS but OS
See all
